Titration: why slow is kind to you

What titration is actually for

Every one of these drugs is started low and increased in steps, and it is worth understanding why, because the reason is not what most people assume.

It is not that a low dose is a trial run to see whether the drug works. It is that the gastrointestinal effects — nausea, fullness, reflux, the lot — are strongly related to how fast the dose rises, and the stepped schedule exists to let your gut catch up with the drug. In the pivotal trials the escalation phase was written into the protocol for exactly this reason: STEP 1 (Wilding, NEJM, 2021) escalated semaglutide over sixteen weeks before anyone sat at the maintenance dose, and SURMOUNT-1 (Jastreboff, NEJM, 2022) escalated tirzepatide in monthly increments.

Tomás, who holds our slow-titrators circle, puts it in one line: the schedule is a schedule, not a law of nature. It was designed to be tolerable for most people in a trial population. You may not be most people.

Why we say slower is a strategy, not a failure

The most common reason people leave these medicines is not that they do not work. It is that the side effects became intolerable and nobody offered an alternative to gritting teeth. In STEP 1 a small but real proportion of participants stopped because of gastrointestinal adverse events, and that trial had a research nurse on the phone; in ordinary life, with a nine-minute appointment and a shortage, people just quietly stop.

So the arithmetic of kindness is simple. A person who stays on a lower dose for eight months is getting treatment. A person who reaches the top of the ladder in four months and abandons it in month five is not. Our circle has both, in numbers, and the second group is generally the one carrying shame about it, which is exactly backwards.

What we cannot do — and Tomás is immovable about this — is tell you a schedule. We are not your prescriber and dose advice from a forum is how people get hurt. What we can do is describe the shape of the conversation that has worked for members, so that you can have your own version of it with the person who is actually responsible for your care.

The conversation that has worked

Members who successfully agreed a gentler path tended to arrive with three things: a description, a pattern, and a question.

A description. Not "I feel rough" but what, when, and for how long. "For the four days after each increase I cannot keep fluids down until evening, and it settles by day five." Specific and unarguable.

A pattern. Two or three cycles written down beats a vivid memory of the worst one. This is the whole argument for keeping a very small diary, and it is why we built the symptom tracker to be five taps rather than a project.

A question, asked as a question. The wordings members report going well include: "Is there room to spend longer at this step?", "What would you need to see from me to consider a smaller increase?", and "If we hold here for now, what would make you want to move?" These invite a clinical judgement instead of asking someone to ratify a decision you have already made.

Mira, our clinical liaison, adds one thing from the other side of the desk: say early in the appointment that you want to continue. Clinicians hear a lot of side-effect reports that are the preamble to stopping, and knowing you want to stay on treatment changes what they offer.

What members have tried, honestly labelled

None of the following is a recommendation and none of it is trial evidence. It is what a few hundred people in our circles have described doing, with their prescribers, and it is offered so that you know what is even possible to ask about.

• Longer at each step. Staying five, six, eight weeks at a dose instead of four before moving. The commonest arrangement by a distance.
• Stopping partway up. Plenty of members have settled at a mid-ladder dose because it was working and comfortable, and never went higher. Nothing in the trials says the top dose is the goal for every person.
• Stepping back down. Going back a rung after a bad fortnight, holding, and then trying again later. Members describe this as the hardest one to ask for and the one that most often rescued their treatment.
• Timing the injection day round the week. Moving the dose so the difficult days fall where life can absorb them. Shift workers in Kiki’s circle have strong opinions on this.
• Symptom-specific help alongside. Anti-nausea medication, laxative choice, reflux treatment. All prescriber territory, all worth asking about rather than enduring.

Does going slower cost you anything

Fair question and the honest answer is: probably some speed, and nobody has run the trial that would tell you how much.

What we know is that the trial results quoted everywhere come from protocols that escalated to a target dose and held it. STEP 1 reported its average of about 14.9 per cent over 68 weeks at semaglutide 2.4 mg. SURMOUNT-1 showed a dose relationship for tirzepatide, with larger average reductions at higher doses. So it is reasonable to think a lower dose does less, on average, over that timescale.

What nobody has studied is the comparison that actually matters to you: a person tolerating a lower dose for two years against the same person abandoning a higher dose in month five. There is no trial of that, and anybody who tells you confidently how it comes out is guessing.

There is also the pragmatic point that dose ladders exist partly for supply and cost reasons in the real world. If you are paying out of pocket, a comfortable lower dose may be the difference between continuing and not, which Petra’s circles could talk about for an hour.

When slower is not the answer

Slowing down is a tolerability strategy for the ordinary tax. It is not a way to manage the small list of symptoms that mean something may be wrong.

Severe abdominal pain, especially the kind that bores through to your back and will not settle. Vomiting you cannot break. Signs of dehydration. Any neurological change. Those do not get titrated around; they get seen, today. The red-flag list is short and worth knowing by heart.

And if the reason you want to move up fast is that the change is not happening quickly enough for your liking, that is a conversation worth having with a person rather than a dial. Ada holds the plateau for exactly this, and the plateau guide is the more useful page than this one.

If you are the one going slowly

A note for people already on a gentler path, because this comes up in circle constantly and deserves saying plainly.

Watching other people climb the ladder while you sit on rung two is a peculiar kind of lonely. It looks like being left behind. It is not — but the feeling is real and pretending otherwise helps nobody, so we talk about it directly in slow-titrators rather than around it.

What long-slow members tend to report, a year or two in, is that the thing they were most afraid of — being on a small dose forever, being a failed case — turned out to be simply their treatment, working, quietly, on a Wednesday. Sam in Portland titrated at half the usual pace and describes it as the decision that made the whole thing survivable. Others found the slow path frustrating and went faster later with better support. Both stories are allowed to stand.